<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Laboratory testing for evaluating a neonate or young infant with suspected cholestatic liver disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Laboratory testing for evaluating a neonate or young infant with suspected cholestatic liver disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Laboratory testing for evaluating a neonate or young infant with suspected cholestatic liver disease</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Finding</td> <td class="subtitle1">Implications</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Initial tests for all infants</td> </tr> <tr> <td class="indent1" colspan="2">Comprehensive metabolic panel</td> </tr> <tr> <td class="indent2"> <ul> <li>Total and conjugated bilirubin</li> </ul> </td> <td>To evaluate for conjugated hyperbilirubinemia (cholestasis) versus unconjugated hyperbilirubinemia.</td> </tr> <tr> <td class="indent2"> <ul> <li>ALT and AST</li> </ul> </td> <td>To assess for hepatocyte injury.</td> </tr> <tr> <td class="indent2"> <ul> <li>Alkaline phosphatase and GGTP</li> </ul> </td> <td>To assess for biliary injury. Furthermore, several genetic/metabolic disorders can be divided into high- and low-GGTP categories<sup>¶</sup>.</td> </tr> <tr> <td class="indent2"> <ul> <li>Total protein and albumin</li> </ul> </td> <td>To assess hepatocyte function. Low albumin suggests poor nutrition, renal losses, or poor hepatic synthetic function.</td> </tr> <tr> <td class="indent2"> <ul> <li>Electrolytes, bicarbonate, glucose</li> </ul> </td> <td>To assess for metabolic disease. Abnormalities in these results are often seen in infants with metabolic disease.</td> </tr> <tr> <td class="indent1">CBC with differential</td> <td>To assess for infection and/or splenic sequestration. Elevated WBC is suggestive of infection. Low WBC and platelet count could indicate portal hypertension (with splenic sequestration).</td> </tr> <tr> <td class="indent1">PT/INR and PTT</td> <td>To assess hepatocyte function and/or vitamin K deficiency. Abnormal results indicate impaired liver synthetic function and/or vitamin K deficiency.</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Additional tests to evaluate for systemic illness of specific liver diseases<sup>Δ</sup></td> </tr> <tr> <td class="indent1">Urinalysis and urine culture</td> <td>Appropriate for most infants with cholestasis to exclude urinary tract infection and to evaluate possible kidney involvement.</td> </tr> <tr> <td class="indent1">Blood culture</td> <td>If clinical presentation suggests sepsis.</td> </tr> <tr> <td class="indent1">Urine-reducing substances</td> <td>Screen for galactosemia (in infants ingesting lactose)<sup>◊</sup>.</td> </tr> <tr> <td class="indent1">Urine succinylacetone</td> <td>Screen for tyrosinemia.</td> </tr> <tr> <td class="indent1">Serum bile acids</td> <td>Elevations are diagnostic of cholestasis. Serum bile acids will be low in infants with bile acid synthetic disorders.</td> </tr> <tr> <td class="indent1">Alpha-1 antitrypsin concentration</td> <td>Low levels suggest alpha-1 antitrypsin deficiency. Normal levels do not exclude alpha-1 antitrypsin deficiency, because this is an acute phase reactant.</td> </tr> <tr> <td class="indent2"> <ul> <li>Protease inhibitor phenotype (PI type)</li> </ul> </td> <td>The primary alleles associated with liver disease are PI*ZZ homozygosity or PI*SZ heterozygosity.</td> </tr> <tr> <td class="indent1">TSH, T4</td> <td>Screen for congenital hypothyroidism (primary or central).</td> </tr> <tr> <td class="indent1">ACTH, cortisol</td> <td>Screen for adrenal insufficiency and hypopituitarism.</td> </tr> <tr> <td class="indent1">Serum ferritin, iron profile including iron, transferrin</td> <td>Elevations suggestive of gestational alloimmune liver disease and hemophagocytic lymphohistiocytosis.</td> </tr> <tr> <td class="indent1">Urine bile acid analysis by FAB-MS</td> <td>Screen for BASD, which may present with low-GGT cholestasis<sup>§</sup>.</td> </tr> <tr> <td class="indent1">Metabolic testing</td> <td>If a metabolic disorder is suspected, initial screening includes creatine kinase, plasma amino acids, urine organic acids, acylcarnitine profile, ammonia, lactate:pyruvate ratio.</td> </tr> <tr> <td class="indent1">Genetic testing</td> <td>Genetic testing is rapidly evolving with the availability of new technologies<sup>¥</sup>. It may include karyotype, targeted gene panels, and/or whole-exome sequencing.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ACTH: adrenocorticotropic hormone; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BASD: bile acid synthetic defects; CBC: complete blood count; FAB-MS: fast atom bombardment mass spectrometry; GGT: gamma-glutamyl transferase; GGTP: gamma-glutamyl transpeptidase; INR: international normalized ratio; PT: prothrombin time; PTT: partial thromboplastin time; T4: thyroxine; TSH: thyroid-stimulating hormone (thyrotropin); WBC: white blood cell count.</p>
<p>¶ GGTP is disproportionately elevated (compared with AST and ALT) in the most common types of neonatal cholestasis, including biliary atresia and Alagille syndrome, while a normal or low GGTP is seen in most forms of progressive familial intrahepatic cholestasis, BASD, and arthrogryposis-renal dysfunction-cholestasis syndrome.</p>
<p>Δ These tests are selected based on the clinical presentation and results of initial tests.</p>
<p>◊ Urine-reducing substances is only valid as a screen for galactosemia if the infant is fed breast milk or a cow's milk-based formula (which contains lactose, then hydrolyzed to galactose).</p>
<p>§ Infants must be off of ursodeoxycholic acid for at least 5 days prior to urine collection for bile acid analysis because the FAB-MS signature of the drug overlaps with some of the abnormal bile acid metabolites seen in BASD.</p>
¥ Individual gene sequencing can be done if the clinical presentation suggests a specific diagnosis, such as Alagille syndrome. For screening of multiple genes associated with inherited cholestasis, next-generation sequencing panels are available. Each panel interrogates approximately 20 to 70 genes. Current information is available at <a href="http://www.GeneTests.org" target="_blank">GeneTests.org</a>.</div><div id="graphicVersion">Graphic 111409 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
